THALES
Thales will provide its SelTrac™ Communications Based Train Control (CBTC) signalling solution in South Korea, Turkey and China, after signing three urban rail signalling contracts. Despite the current Covid-19 pandemic, governments around the globe are committed to progressing forward with crucial public transportation developments and Thales’s technology will be an important part of these projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005010/en/
Incheon Metro, Line 2 Capacity Increase
Incheon Subway Line 2 is part of the overall Seoul Metropolitan Subway network, which is currently undergoing modernisation to improve the performance and reliability of the network.
Thales has signed a contract with DaeaTi, a leading Korean railway signalling technology player, to provide new signalling equipment for the Incheon Line 2 depot capacity increase, which will address the need to park the six new driverless trains safely. The trains will be delivered in 2021 with Thales’ Vehicle On Board Controller (VOBC) which were separately contracted with train contractor Woojin Ind in 2019. Since the start of revenue service of Incheon’s L2 metro in July 2016, passenger flow has doubled from 90,000 to 180,000 a day, prompting the need for six additional trains to cope with the increase.
Thales has been working with Incheon City and Incheon Transit Corporation since 2009 on the Incheon Line 2, focusing on better serving the public transit users of Incheon as their common goal.
Istanbul Metro, Line M10
The M10 Line will be the first metro line to the Sabiha Gokcen International Airport, the second busiest airport in Turkey, on the Asian side of Istanbul and will comprise 7.5km of track and four stations. Gülermak-YSE Joint Venture is the main project contractor, and Thales has been contracted by Çelikler Taahhut, a major construction company, to install their SelTrac™ CBTC system on the new M10 Line in Istanbul Turkey, connecting the Kaynarca district and the Sabiha Gokcen Airport. The M4 line is already equipped with Thales’s SelTrac™ solution and the new contract will extend the existing technology onto the new line.
Upon completion, the new line will allow connectivity between the Airport and major cities, taking 13 minutes from the airport to Kaynarca, 46 minutes to Kadikoy and an hour to Yenikapı, on the European side. This project is part of the Government of Turkey’s key priorities to improve transportation in major cities , with a strong focus on connectivity between transportation hubs.
Nanchang Metro, Line 4
Thales SEC Transportation System Company Limited (TST), Thales’ Joint Venture with Shanghai Electric, will provide the signalling for the first phase of the new metro Line 4 in Nangchang, the capital and largest city of the Jiangxi Province in eastern China. The first phase of the Nanchang Metro Line 4 will expand from Baimashan Station to Yuweizhou Station, passing through the main area of Nanchang to connect five districts. The first phase of the Nanchang Metro Line 4 has a total operational length of 39.6km, with 34.1km underground, 5.5km elevated and 29 stations, making it the longest metro line in Nanchang, with the largest number of stations. .
TST is familiar with the network as they have previously delivered signalling systems to the Line 1 and Line 2 of the Nangchang Metro. This project will allow the Nanchang Metro to continue to support the rapidly growing population of Nanchang.
In parallel in China, on April 23rd, Hangzhou Metro Line 16, connecting Hangzhou downtown with Lin’an District, entered into revenue service smoothly. This very fast metro line relies on Thales SEC Transport signalling system technologies for maximum safety and efficiency, ensuring everyday pleasant and reliable journeys for local passengers and showing Thales commitment to China ground transportation.
“During the Covid-19 period, we are continuing to work together with our global partners in major cities such as Incheon, Istanbul, and Nanchang. Thales is committed to providing state-of-the-art SelTrac™ CBTC signalling technology. No matter the network or city, we continue to tailor our solution to meet the needs of the customer and provide reliable transportation solutions for their passengers.” – Dominique Gaiardo, Vice President and Managing Director for Thales’ urban rail signalling business.
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Transportation
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom